Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Dyne Therapeutics

DYN

24.8903.90% ( -1.010 )

Trading: Jul 29, 13:43:03 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Dyne Therapeutics: Buy Rating Reiterated as FORCE Platform Expands; $47 Price Target Maintained
Tip Ranks·5 hours ago
DYN-3.90%
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Unusual Whales·1 day ago, 06:34 AM
DYN-3.90%
Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,
rttnews·1 day ago, 03:30 AM
SLN-1.65%LH-1.21%
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News
StockTitan·Jul 24 at 07:05 AM
DYN-3.90%
Dyne Therapeutics closes upsized public offering of 21,045,000 shares at $20.5 each
PUBT·Jul 23 at 03:29 PM
DYN-3.90%EVR-9.81%
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Unusual Whales·Jul 23 at 03:08 PM
DYN-3.90%
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway
Tip Ranks·Jul 22 at 04:51 PM
DYN-3.90%
Dyne Therapeutics slides 3% in regular trading on earnings pressure
US Stock Market Update·Jul 22 at 01:50 PM
DYN-3.90%
Dyne Therapeutics falls 7% during regular trading on earnings pressure
US Stock Market Update·Jul 22 at 11:11 AM
DYN-3.90%
Biggest stock movers Wednesday: SMCI, DYN, GEV, T, and more
MSN·Jul 22 at 09:05 AM
GEV-4.07%GOOGL+0.71%
Dyne Therapeutics falls 6% during regular trading on earnings concerns
US Stock Market Update·Jul 22 at 08:51 AM
DYN-3.90%